Bribery allegations hang over Biomet/Zimmer; FDA clears 31 digital health apps in 2014;

> Bribery allegations in Brazil and Mexico hang over Biomet, tainting its acquisition by Zimmer ($ZMH). The New York Times details the background and how regulators might address them to allow the deal to go forward. Story

> Interleukin Genetics raised $10 million, half in debt and half in equity, to market its genetic tests including one to determine predisposition to severe periodontal disease. The debt is from Horizon Technology Finance ($HRZN), while the equity it from New Enterprise Associates and Bay City Capital. Release

> Sinus dilation player Entellus Medical filed to raise up to $69 million in a public offering, but coronary artery disease test maker CardioDx withdrew its IPO after securing $35M in private financing earlier this week.

> Mobihealthnews has a roundup and analysis of all 31 digital health apps cleared by FDA in 2014. More

> India will now allow foreign companies to acquire India-based medical device companies. Story

> Corgenix Medical ($CONX) received two grants for a total of $818,000 for the development of an Ebola rapid diagnostic kit from the Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation. Release

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.